Literature DB >> 32487466

Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients.

Won Jong Chwa1, Todd A Tishler2, Catalina Raymond3, Cathy Tran2, Faizan Anwar2, J Pablo Villablanca3, Joseph Ventura2, Kenneth L Subotnik2, Keith H Nuechterlein4, Benjamin M Ellingson5.   

Abstract

This cross-sectional study examines the differences in cortical volume and gray-to-white matter contrast (GWC) in first episode schizophrenia patients (SCZ) compared to healthy control participants (HC) and in SCZ patients as a function of exposure to second generation antipsychotic medication. We hypothesize 1) SCZ exhibit regionally lower cortical volumes relative to HCs, 2) cortical volume will be greater with longer exposure to second generation antipsychotics prior to the MRI scan, and 3) lower GWC with longer exposure to second generation antipsychotics prior to the MRI scan, suggesting more blurring from greater intracortical myelin. To accomplish this, MRI scans from 71 male SCZ patients treated with second generation oral risperidone and 42 male HCs were examined. 3D T1-weighted MPRAGE images collected at 1.5T were used to estimate cortical volume and GWC by sampling signal intensity at 30% within the cortical ribbon. Average cortical volume and GWC were calculated and compared between SCZ and HC. Cortical volume and GWC in SCZ patients were correlated with duration of medication exposure for the time period prior to the scan. First-episode SCZ patients had significantly lower cortical volume compared to HCs in bilateral temporal, superior and rostral frontal, postcentral gyral, and parahippocampal regions. In SCZ patients, greater cortical volume was associated with (log-transformed) duration of second-generation antipsychotic medication exposure in bilateral precuneus, right lingual, and right superior parietal regions. Lower GWC was correlated with longer duration of medication exposure bilaterally in the superior frontal lobes. In summary, second generation antipsychotics may increase cortical volume and decrease GWC in first episode SCZ patients.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cortical volume; Intracortical myelin; Schizophrenia; Second generation antipsychotics

Mesh:

Substances:

Year:  2020        PMID: 32487466      PMCID: PMC7572538          DOI: 10.1016/j.schres.2020.03.073

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  104 in total

1.  Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia.

Authors:  L E DeLisi; M Sakuma; W Tew; M Kushner; A L Hoff; R Grimson
Journal:  Psychiatry Res       Date:  1997-07-04       Impact factor: 3.222

2.  Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.

Authors:  Robin Emsley; Jonathan Rabinowitz; Rossella Medori
Journal:  Schizophr Res       Date:  2006-11-07       Impact factor: 4.939

3.  Improved Localizadon of Cortical Activity by Combining EEG and MEG with MRI Cortical Surface Reconstruction: A Linear Approach.

Authors:  A M Dale; M I Sereno
Journal:  J Cogn Neurosci       Date:  1993       Impact factor: 3.225

4.  The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies.

Authors:  Antonio Vita; Luca De Peri; Giacomo Deste; Stefano Barlati; Emilio Sacchetti
Journal:  Biol Psychiatry       Date:  2015-02-16       Impact factor: 13.382

5.  Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

Authors:  Wiepke Cahn; Hilleke E Hulshoff Pol; Elleke B T E Lems; Neeltje E M van Haren; Hugo G Schnack; Jeroen A van der Linden; Patricia F Schothorst; Herman van Engeland; René S Kahn
Journal:  Arch Gen Psychiatry       Date:  2002-11

6.  Incidence of tardive dyskinesia: five-year data from a prospective study.

Authors:  J M Kane; M Woerner; P Weinhold; J Wegner; B Kinon; M Borenstein
Journal:  Psychopharmacol Bull       Date:  1984

Review 7.  Tardive dyskinesia and new antipsychotics.

Authors:  Christoph U Correll; Eva M Schenk
Journal:  Curr Opin Psychiatry       Date:  2008-03       Impact factor: 4.741

Review 8.  Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis.

Authors:  G Désaméricq; F Schurhoff; A Meary; A Szöke; I Macquin-Mavier; A C Bachoud-Lévi; P Maison
Journal:  Eur J Clin Pharmacol       Date:  2013-10-22       Impact factor: 2.953

9.  Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.

Authors:  K H Nuechterlein; M E Dawson; M Gitlin; J Ventura; M J Goldstein; K S Snyder; C M Yee; J Mintz
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

10.  Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: a postmortem morphometric study.

Authors:  Natalya A Uranova; Olga V Vikhreva; Valentina I Rachmanova; Diana D Orlovskaya
Journal:  Schizophr Res Treatment       Date:  2011-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.